Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates

A US biotech company has announced a further $187.5 million in cash and cash equivalents for the first half of 2023, according to the latest figures from the US Department of Pharmaceuticals and Healthcare (DHS) in the Lancet.

Published on 2023-05-01